SARS-CoV-2 Antibodies in Children with Chronic Disease from a Pediatric Gastroenterology Outpatient Clinic
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: At the beginning of the Coronavirus disease (COVID-19) epidemic, physicians paid close attention to children with chronic diseases to prevent transmission or a severe course of infection. We aimed to measure the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody levels in children with chronic gastrointestinal and liver diseases to analyze the risk factors for infection and its interaction with their primary disease. Methods: This cross-sectional study analyzed SARS-CoV-2 antibody levels in patients with gastrointestinal and liver diseases (n=141) and in healthy children (n=48) between January and February 2021. Results: During the pandemic, 10 patients (7%) and 1 child (2%) had confirmed COVID-19 infection (p=0.2). The SARS-CoV-2 antibody test was positive in 36 patients (25.5%) and 11 children (22.9%) (p=0.7). SARS-CoV-2 antibody positivity was found in 20.4%, 26.6%, 33.3%, and 33.3% of patients with chronic liver diseases, chronic gastrointestinal tract diseases, cystic fibrosis, and liver transplantation recipients, respectively (p>0.05, patients vs. healthy children). Risk factors for SARS-CoV-2 antibody positivity were COVID-19-related symptoms (47.2% vs. 14.2%, p=0.00004) and close contact with SARS-CoV-2 polymerase chain reaction-positive patients (69.4% vs. 9%, p<0.00001). The use, number, and type of immunosuppressants and primary diagnosis were not associated with SARS-CoV-2 antibody positivity. The frequency of disease activation/flare was not significant in patients with (8.3%) or without (14.2%) antibody positivity (p=0.35). Conclusion: SARS-CoV-2 antibodies in children with chronic gastrointestinal and liver diseases are similar to that in healthy children. Close follow-up is important to understand the long-term effects of past COVID-19 infection in these children.
Abstract
Purpose: At the beginning of the Coronavirus disease (COVID-19) epidemic, physicians paid close attention to children with chronic diseases to prevent transmission or a severe course of infection. We aimed to measure the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody levels in children with chronic gastrointestinal and liver diseases to analyze the risk factors for infection and its interaction with their primary disease. Methods: This cross-sectional study analyzed SARS-CoV-2 antibody levels in patients with gastrointestinal and liver diseases (n=141) and in healthy children (n=48) between January and February 2021. Results: During the pandemic, 10 patients (7%) and 1 child (2%) had confirmed COVID-19 infection (p=0.2). The SARS-CoV-2 antibody test was positive in 36 patients (25.5%) and 11 children (22.9%) (p=0.7). SARS-CoV-2 antibody positivity was found in 20.4%, 26.6%, 33.3%, and 33.3% of patients with chronic liver diseases, chronic gastrointestinal tract diseases, cystic fibrosis, and liver transplantation recipients, respectively (p>0.05, patients vs. healthy children). Risk factors for SARS-CoV-2 antibody positivity were COVID-19-related symptoms (47.2% vs. 14.2%, p=0.00004) and close contact with SARS-CoV-2 polymerase chain reaction-positive patients (69.4% vs. 9%, p<0.00001). The use, number, and type of immunosuppressants and primary diagnosis were not associated with SARS-CoV-2 antibody positivity. The frequency of disease activation/flare was not significant in patients with (8.3%) or without (14.2%) antibody positivity (p=0.35). Conclusion: SARS-CoV-2 antibodies in children with chronic gastrointestinal and liver diseases are similar to that in healthy children. Close follow-up is important to understand the long-term effects of past COVID-19 infection in these children.
참고문헌 (22)
- Wu Z, "Characteristics of and important lessons from the coronavirus disease 2019(COVID-19)outbreak in China : summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention", JAMA, 323, pp.1239~1242 (2020)
- Ludvigsson JF, "Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults", Acta Paediatr, 109, pp.1088~1095 (2020)
- Akobeng AK, "Gastrointestinal manifestations of COVID-19 in children : a systematic review and meta-analysis", Frontline Gastroenterol, 12, pp.332~337 (2020)
- Tullie L, "Gastrointestinal features in children with COVID-19 : an observation of varied presentation in eight children", Lancet Child Adolesc Health, 4, pp.e19~20 (2020)
- Cheung KS, "Gastrointestinal manifestations of SARSCoV-2 infection and virus load in fecal samples from a Hong Kong cohort : systematic review and metaanalysis", Gastroenterology, 159, pp.81~95 (2020)
- Assa A, "Gastrointestinal Committee of ESPGHAN. Gastrointestinal perspective of coronavirus disease 2019 in children-an updated review", J Pediatr Gastroenterol Nutr, 73, pp.299~305 (2021)
- "Elecsys® Anti-SARS-CoV-2 S assay" (2022)[URL]
- Di Giorgio A, "COVID-19 in children with liver disease", Front Pediatr, 9 (2021)
- Sansotta N, "Children with inflammatory bowel disease in the COVID-19 main endemic focus : the Lombardy experience", Front Pediatr, 9, pp.607285~ (2021)
- Yuksel M, "A single-center report of COVID-19 disease course and management in liver transplanted pediatric patients", Pediatr Transplant, 25, pp.e14061~ (2021)
- Corrias A, "Risk, course, and effect of SARS-CoV-2infection in children and adults with chronic inflammatory bowel diseases", Children(Basel), 8, pp.753~ (2021)
- Marjot T, "COVID-19 and liver disease : mechanistic and clinical perspectives", Nat Rev Gastroenterol Hepatol, 18, pp.348~364 (2021)
- Nicastro E, "The impact of severe acute respiratory syndrome coronavirus type 2 on children with liver diseases : a joint European Society for Pediatric Gastroenterology, Hepatology and Nutrition and Society of Pediatric Liver Transplantation position paper", J Pediatr Gastroenterol Nutr, 74, pp.159~170 (2022)
- Kehar M, "Severe Acute respiratory syndrome coronavirus-2 infection in children with liver transplant and native liver disease : an international observational registry study", J Pediatr Gastroenterol Nutr, 72, pp.807~814 (2021)
- Di Giorgio A, ""Health status of children with chronic liver disease during the SARS-CoV-2 outbreak : results from a multicentre study"", Clin Res Hepatol Gastroenterol, 45, pp.101610~ (2021)
- Tannuri U, "Low incidence of COVID-19 in children and adolescent post-liver transplant at a Latin American reference center", Clinics(Sao Paulo), 75, pp.e1986~ (2020)
- Buescher G, "SARS-CoV-2 in pediatric liver transplant recipients : the European experience", J Pediatr Gastroenterol Nutr, 74, pp.41~42 (2022)
- Sin P, "Acute liver injury among pediatric liver transplantation recipients with coronavirus disease 2019: an international collaborative study", J Pediatr Gastroenterol Nutr, 74, pp.391~394 (2022)
- Cakir M, "New-onset celiac disease in children during COVID-19 pandemic", Acta Paediatr, 111, pp.383~388 (2022)
- Colmenero J, "Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients", J Hepatol, 74, pp.148~155 (2021)
- Romanelli A, "Immunosuppression drug-related and clinical manifestation of Coronavirus disease 2019 : a therapeutical hypothesis", Am J Transplant, 20, pp.1947~1948 (2020)
- Turner D, "Paediatric IBD Porto group of ESPGHAN. Corona virus disease 2019 and paediatric inflammatory bowel diseases: global experience and provisional guidance (March 2020) from the Paediatric IBD Porto Group of European Society of Paediatric Gastroenterology, Hepatology, and Nutrition", J Pediatr Gastroenterol Nutr, 70, pp.727~733 (2020)